

**PREVALENCE OF CHLAMYDIA TRACHOMATIS INFECTION IN INFERTILE WOMEN ATTENDING FERTILITY CLINICS IN BENIN CITY, NIGERIA: A PUBLIC HEALTH CONCERN**

**AKINNIBOSUN, F. I. and ONYEMEKEIHIA, O. H**

**Department of Microbiology, Faculty of Life Sciences, University of Benin, P. M. B 1154,  
Benin City, Edo State, Nigeria.**

**ABSTRACT**

This study was carried out to deduce the prevalence of *Chlamydia* infection amongst infertile women attending fertility clinics in Benin City, Nigeria. Fifty infertile women with either primary or secondary infertility and with their ages ranging from 24 to 51 years were enrolled for this study. The serum of each patient was screened for *Chlamydia* antibodies with the enzyme-linked immune-sorbent assay (ELISA) and immunoglobulin G (IgG) index of 0.90 or less was reported as seronegative for IgG antibody, while IgG index of 1.00 or greater were positive for IgG antibody. Findings in the present study revealed that 24 % to 52 % of the patients that attend the fertility clinics in Benin City, Nigeria were most likely to be infected with *Chlamydia*; with the primary infertile patients accounting for 32 % of the cases and secondary infertile patients for 68 % of the cases. Prevalence of *Chlamydia* infection was also found to be quite high amongst women aged between 36 and 40 years old. Since lack of symptoms often makes the clinical diagnosis of *Chlamydia* infection somewhat difficult, thus increasing the prevalence of this disease; routine screening is recommended to enable early therapeutic interventions of positive cases.

**KEY WORDS:** Infertility; *Chlamydia* infection; Asymptomatic; Immunoglobulin; Enzyme linked immune-sorbent assay.

\*Corresponding author email: [faith.akinnibosun@uniben.edu](mailto:faith.akinnibosun@uniben.edu) Tel +234(0)8146247781

## INTRODUCTION

*Chlamydia trachomatis*, an obligate intracellular human pathogen, is one of four bacterial species in the genus *Chlamydia*. It is a Gram-negative bacterium. It can appear as either coccoid or rod-shaped (Paavonen *et al.*, 1999). *Chlamydia trachomatis* infection is the most prevalent sexually-transmitted bacterial infection worldwide (Paavonen *et al.*, 1999). It is found only in humans and it is estimated that about one million individuals in the United States are infected with *Chlamydia*. According to the World Health Organization, more than 90 million *Chlamydia* infections are detected annually worldwide (Gerbase *et al.*, 1998). *Chlamydial* infections cause major medical, social and economic problems. Untreated *chlamydial* infections can cause serious reproductive and other health problems with both short-term and long-term consequences (Emeleet *et al.*, 2009). Like other sexually-transmitted infections, *chlamydial* infection is primarily a woman's health care issue since the manifestations and sequelae have more adverse effects on female reproductive health than on the male (Paavonen *et al.*, 1999.).

*Chlamydia* species are obligate intracellular parasites (Brooks *et al.*, 2007; Korhonen *et al.*, 2012; Eschenbach *et al.*, 1984). Eighteen distinct serotypes of *C. trachomatis* have been currently identified. Serotypes D to K are known to cause sexually-transmitted genital infections and neonatal infections. *Chlamydial* infection begins by contact of infectious elementary

body [EB] with the apical epithelial surface of a target cell (Beatty *et al.*, 1994). The specific interaction triggers a series of early events which helps to program the *Chlamydia* and also prime the host cell for productive infection. Proposed mechanisms of *Chlamydia* uptake are parasite-specific phagocytosis,

receptor-mediated endocytosis and pinocytosis (Oakeshott *et al.*, 1992). Genital infection caused

by *C. trachomatis* is generally asymptomatic. Approximately 50 % of infected males and 80 % of infected females show no symptoms, but infection may cause a muco-purulent cervicitis in females and urethritis in males (Ingalis *et al.*, 1995). Commonly unrecognized and often poorly or inadequately treated, *Chlamydia* infections can ascend the reproductive tract resulting in pelvic inflammatory disease (PID) and, consequently, lead to chronic pelvic pain, ectopic pregnancy, and infertility (Chernesky, 2005).

Women with a *Chlamydia* infection (especially serotype G) are 6.5 times more likely to develop cervical cancer than those without infection (Anttila *et al.*, 2001). In women with recent or invasive *Chlamydia* infection, increased rates of preterm delivery, premature rupture of membranes, low birth weight, and still birth have been observed (McGregor and French, 1991). Infection with *C. trachomatis* is also implicated in post-abortion, post-Cesarean section, and postpartum maternal infections. *C. trachomatis* in the cervix may be transmitted to a neonate during vaginal delivery, resulting in conjunctivitis and during vaginal delivery, resulting in conjunctivitis and neonatal pneumonia. *Chlamydia* infection develops in 60 % of neonates born vaginally to infected mothers. Premarital sexual intercourse and intercourse with multiple partners have been shown to be significant risk factors for *C. trachomatis* as well as HIV infection (Hitchcock, 1999). *C. trachomatis* infection can be transmitted through vaginal, anal, or oral sexual or all sexual intercourse and also vertically during childbirth. The greater the number of sexual partners, the greater the risk of infection (Williams *et al.*, 2003). Young age and multiple sexual partners have been identified as risk

factors for chlamydial infection (Williams et al., 2003). *C. trachomatis* infection is the major cause of mucopurulent cervicitis (MPC) and pelvic inflammatory disease (PID) in women (Rose et al., 2007; Ainbinder et al., 2007; Opaneye et al., 2003). Chlamydial MPC can lead to some complications which include ascending intraluminal spread of organisms from the cervix, producing PID, ascending infection during pregnancy resulting in premature rupture of the membrane, chorioamnionitis, premature delivery, and puerperal and neonatal infections (McCormack, 1994; Beem et al., 1977; Martin et al., 1982). An increasing proportion of cases with chlamydial PID are atypical or silent (Hiltunen et al., 1998). Chlamydial PID is the most important preventable cause of infertility, including tubal factor infertility, and adverse pregnancy outcome (Weström, 1994). Studies have demonstrated an association between serum antibodies (Ab) to *C. trachomatis* and tubal factor infertility or ectopic pregnancy (Cates et al., 1991). Some studies have revealed that the severity of tubal damage found in infertile women is directly related to serum antibody titer levels (Punnonen et al., 1979; Mol et al., 1997). Nucleic acid amplification tests (NAAT) is considered the tests of choice for diagnosing *C. trachomatis* infection (Puolakkainen et al., 1998; Black, 1997). Serological detection of antibodies to *Chlamydia trachomatis* constitutes a convenient and yet highly sensitive approach to the diagnosis of Chlamydial infections (Johnson et al., 2008). The micro-immunofluorescence (MIF) assay, which detects antibodies to Chlamydial elementary bodies, is also used for serodiagnosis of *C. trachomatis*. Anti-

chlamydial IgG antibodies are used as

markers for previous exposure to these microorganisms and the IgA antibodies

serve as markers for existing mucosal infection. Infertility is an emerging health problem in many countries of the world including Nigeria. The increase appears to coincide with the growing role played by *C. trachomatis* as a sexually transmitted disease.

Fertility clinics in Benin City, Nigeria, experience nowadays, increase in infertile couples with increasing challenge to meet their health care needs. Since *Chlamydia* has been shown to affect fertility outcome, it became secondary infertility and within the age group of 36 to 40 years. Lack of symptoms often makes clinical diagnosis of *Chlamydia* infection somewhat difficult. Thus, routine screening is recommended to enable early imperative to evaluate the prevalence of *Chlamydia trachomatis* amongst infertile couples in this research, so as to suggest ways of improving care and treatment outcome. The findings from this study would be an added advantage for the management of infertile women.

## MATERIALS AND METHODS

### Sample collection and processing

The study population comprised of all infertile woman attending fertility clinic for the first time from January to March 2015, who consented to the screening process. In this study, a total of fifty women with primary and secondary infertility were investigated. Detailed clinical history of each patient was recorded. Five milliliter of blood

was collected from each patient and serum was separated by centrifugation at 2,500 rpm for 15 minutes followed by subsequent screening for *Chlamydia*. The sera were tested for *Chlamydia* antibodies using ELISA IgG kits (Diagnostic Automation, Inc., California United States). One milliliter of the *Chlamydia* antiserum was added to 0.5 ml of patient serum (test), while 0.5 ml of patient serum was added to 1 ml of *Chlamydia* standard solution (standard) followed by incubation for 30 minutes at 37°C and measurement with the spectrophotometer at a wavelength of 370 - 450 nm. The *Chlamydia* level (*Chl*) was subsequently deduced as follows:  $chl = \frac{\text{Test absorbance}}{\text{Standard absorbance}} \times 10.4$

*Standard absorbance*

**Interpretation of results:** IgG index of 0.90 or less were sero-negative for IgG antibody, while IgG index of 1.00 or greater were positive for IgG antibody.

## RESULTS AND DISCUSSION

As indicated by the confidence interval (Table 1), 24 % to 52 % of the patients that attend the fertility clinics in Benin City, Nigeria were most likely to be infected with *Chlamydia*; with the primary infertile patients accounting for 32 % of the cases and secondary infertile patients for 68 % of the cases. The findings in the present study revealed a high prevalence of *Chlamydia* infection which agreed with the work of Sturm-Remirex et al., 2002.

**Table 1** Prevalence of *Chlamydia* infections in infertile women attending fertility clinics in Benin City, Nigeria

Fertility clinics in Benin City, Nigeria								
Prevalence of <i>Chlamydia</i> infection			Patients with primary infertility			Patients with secondary infertility		
(N=50)			(P=19)			(P=19)		
Mean	S. Error	95 % CI	Mean	S. Error	95 % CI	Mean	S. Error	95 % CI
(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)	(x 100 %)
0.31	0.07	24-0.25	0.32	0.11	10-0.25	0.68	0.11	0.45-0.91

N: the total numbers of infertile women from who blood samples were collected for screening. P: the total number of positive cases. S: standard. CI: confidence interval.

There was a wide variation in the prevalence of *C. trachomatis* which may be dependent on the age, marital status, clinical condition, sensitivities of the methods used, and various other factors (Buye et al., 2001; Verkoyeen et al., 2002). *C. trachomatis* infections have been shown to be asymptomatic with undetected or multiple infection in up to 70% women population who are at risk of developing a severe reproductive sequelae infection which agreed with the work of Sturm-Ramirex et al. (2002). including pelvic inflammatory disease and tubal infertility (Carey and Beagly, 2010), indicating that the infection was a silent epidemic. In most part of Nigeria, *C. trachomatis* are not routinely screened for, and hence relative information about frequencies of the organisms is scarce. There is need therefore for routine screening of women for *Chlamydia* and subsequent treatment to protect them from prolonged infection which could have effect on fertility due to tubal blockage. History of infertility and pelvic inflammatory disease, other sexually transmitted diseases and spontaneous abortion have been associated with the of infection with *C. trachomatis* (Geisler, 2006). The distribution of positive cases of *Chlamydia* infection amongst the different age groups, as presented in Table 2, ranged between 37 % in the 36 - 40 years age group and 5 % in the 25 - 30 years age group.

**Table 2** Distribution of positive cases among the different age groups of infertile women.

Age groups (Years)	Distribution of positive cases (P=19)		
	Mean (x 100 %)	S, Error (x 100 %)	95% CI (x 100 %)
25-30	0.05	0.05	0.00-0.16
31-35	0.21	0.10	0.01-0.41
36-40	0.37	0.11	0.13-0.61
41-45	0.16	0.09	0.00-0.34
>45	0.21	0.10	0.01-0.41

P: the total number of positive cases. S: standard error. CI: confidence interval.

From the results obtained in this study, it can be seen that the prevalence of *Chlamydia* infection

was quite high amongst women aged between 36 and 40 years old. This may indicate higher sexual activity and low or no use of barrier (condom) method of contraception in this age group (Alarape *et al.*, 1998). This present finding agreed with the views by Kotchick *et al.* (2001), that *C. trachomatis* can be transmitted through sexual intercourse. It can be deduced that the females must have contacted the infection through sex or contact with contaminated surfaces such as toilet seats (Parks *et al.*, 1997; Kotchick *et al.*, 2001). Widespread utilization of more accurate tests like nucleic acid amplification for detection of infected genital secretions in those attending the sexually transmitted infection or general gynecological clinics for infertility are presently nonexistent in Nigeria and many developing countries, and their use should be encouraged since this is perhaps a better way of detecting and treating asymptomatic *C. trachomatis*, which is still highly prevalent in apparently healthy population, especially the more sexually active population. Measures such as the use of barrier method during sexual intercourse, limiting the number of sexual partners, public awareness, school involvement, and peer educators may help in reducing the disease prevalence.

## CONCLUSION

A relatively high frequency of *Chlamydia* infections was observed in infertile patients in Nigeria, especially in patients with secondary infertility and within the age group of 36-40 years. Lack of symptoms often makes clinical diagnoses of chlamydia infection somewhat difficult. Thus routine screening is recommended to enable early therapeutic interventions.

## ACKNOWLEDGEMENTS

The authors are grateful to Department of Microbiology, Faculty of Life Sciences, University of Benin, Benin City, for provision of materials for this work.

## REFERENCES

- Ainbinder SW, Ramin SM, DeCherney AH (2007). *Sexually transmitted diseases and pelvic infections*. In: DeCherney AH, Nathan L, Goodwin TM, Laufer N (Editors). *Current Diagnosis and Treatment Obstetrics and Gynecology* 10th edition. New York: Mc- Graw-Hill Companies Inc. 662-695pp.
- Anttila T, Saikku P, Koskela P, Bloigu A, Dillner J, Ikkäheimo I. (2001). Serotypes of *Chlamydia trachomatis* and risk development of cervical squamous cell carcinoma. *JAMA* **285**:47-51.
- Aseffa A, Ishak A, Stevens R, Fergusson E, Giles M, Yohannes G (1998). Prevalence of HIV, syphilis and genital *Chlamydia* infection among women in North-West

Ethiopia. *Epidemiology and Infection* 120:171-177.

Beatty WL, Morrison RP, Byrne GI (1994). Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. *Microbiological Reviews* 58: 686-699.

Beem. MO, Saxon EM (1977). Respiratory-tract colonization and a distinctive pneumonia syndrome in infants infected with *Chlamydia trachomatis*. *New England Journal of Medicine* 296: 306-310.

Black CM (1997). Current methods of laboratory diagnosis of *Chlamydia trachomatis* infection. *Clinical Microbiology Review* 10: 160-184.

Brooks GF, Carroll KC, Butel JS and Morse SA (2007). *Chlamydiae*. In: Jawetz, Melnick and Adelberg's Medical Microbiology 24th edition. New York, USA: Mc-Graw Hill Companies Inc. 357-366.

Buve A, Weiss HA, Laga M, Van Dyck E, Musonda R, Zekeng L (2001). The epidemiology of gonorrhoea, *Chlamydia* infection and syphilis in four African countries. *AID* 15:579-588.

Carey, A.J. and Beagly, K.W. (2010). *Chlamydia trachomatis*, a hidden epidemic: effects on female reproduction and options for treatment. *American Journal of Reproductive Medicine* 63(6): 360 - 363.

Cates W, Wasserheit JN. (1991). Genital chlamydial infections: epidemiology and reproductive

sequelae. *American Journal of Obstetrics & Gynecology* 164: 1771-1781.

Cheesbrough M. (2005). *District Laboratory Practice in Tropical Countries*. Cambridge University Press, United Kingdom. 30 - 41pp.

Chernesky MA. The laboratory diagnosis of *Chlamydia trachomatis* infection. (2005). *Canadian Journal of Infectious Disease and Medical Microbiology* 16: 39-44.

Emele FE, Anaghalu IC, Adinma, E.D, Okonkwo JEN. (2009). Prevalence of chlamydia trachomatis antibodies

among infertile women in Anambra state, Nigeria. *Nigeria Journal of Medicine and Biomedical Research* 4(1): 16-18.

Eschenbach DA. (1984). Acute Pelvic Inflammatory Disease. *Urologic Clinics of North America* 11(1): 65-81.

Geisler WM. (2006). Management of uncomplicated *Chlamydia trachomatis* infections in adolescents and adults: evidence reviewed for the Center for Disease Control and Prevention sexually transmitted diseases treatment guidelines. *Clinical Infectious Disease* 3: 577 - 581.

Gerbase AC, Rowley JT, Mertens TE. (1998). Global epidemiology of sexually transmitted diseases. *Lancet* 351: 2 - 4.

Hiltunen-Back E, Rostila T, Kautiainen H, Paavonen J, Reunala T. (1998). Rapid decrease of epidemic gonorrhoea in Finland. *Sex Journal of Transmitted Diseases* 25: 181-186

Hitchcock PJ. (1999). Future directions of *Chlamydial* research In: Stephens RS,

editor. *Chlamydia* intracellular biology. Pathogenesis and immunity. Washington

DC: American Society for Microbiology pp 297-311.

Ingalis RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenback DT. (1995). The inflammatory cytokine response to *Chlamydia trachomatis* infection is endotoxin mediated. *Infection and Immunology* **63**: 3125-3130.

Johnson A. and Horner P. (2008). A new role for *C. trachomatis* serology? *Sexually Transmitted Infection* **84**: 79-80.

Korhonen JT, Puolakkainen M, Haveri A, Tammiruusu A, Sarvas M, Laheesmaa R. (2012).

*Chlamydia pneumoniae* entry into epithelial cells by clathrin-independent endocytosis. *Journal of Microbial Pathogenesis* **52**(3): 157-164.

Kotchick BA, Shaffer A, Forhand R, Miller KS. (2001). Adolescent sexual risk behaviour: A multi system perspective. *Clinical Psychology Review* **21**(4): 493-519.

Martin DH, Koutsky L, Eschenbach DA, Daling JR, Alexander ER, Benedetti JK. (1982). Prematurity and perinatal mortality in pregnancies complicated by maternal *Chlamydia trachomatis* infections. *Journal of the American Medical Association* **247**: 1585-1588.

Mawak JD, Dashe N, Agabi YA, Panshak BW. (2011). Prevalence of Genital *Chlamydia trachomatis* among Gynecologic Clinic attendees in Jos, Nigeria. *Shiraz E-medical journal. Shiraz Iran* **12**: 2-7.

McCormack WM. (1994). Pelvic inflammatory disease. *New England Journal of Medicine* **330**: 115-119.

McGregor JA, French JI. (1991). *Chlamydia trachomatis* infection during pregnancy.

*American Journal of Obstetrics and Gynecology* **164**: 1782-1789.

Mol BV, Dijkman B, Wertheim P, Lijmer J, van der Veen F, Bossuyt PM. (1997). The accuracy of serum chlamydial antibodies in the diagnosis of tubal pathology: a meta-analysis. *Fertility and Sterility Forum* **67**: 1031-1037.

Oakeshott P, Chiverton S, Speight L, Bertrand J. (1992). Testing for cervical *Chlamydia trachomatis* infection in an inner city practice. *Family Practice* **9**: 421-424.

Opaneye AA. Pelvic infections. In: Okonofua F, Odunsi K (Editors). (2003). *Contemporary Obstetrics and Gynaecology for Developing Countries*. Benin City, Nigeria: Women's Health and Action Research Centre pp.54-65.

Paavonen J, Anttila T, Koskela P. (1998). *Chlamydia trachomatis* and cervical cancer. In: Stephens, R.S., Byrne, G.I., Christiansen, G. E. (Editors). *Proceedings of the Ninth International Symposium on Human Chlamydial Infection* pp.39-42.

Paavonen J, Eggert-Kruse W. (1999). *Chlamydia trachomatis*: impact on human reproduction. *Human Reproduction Update* **5**(5): 433-447.

Parks KS, Dixon PB, Richey CM, Garlo GG, Alpha O, Soon J, Chaw SJ. (1997). Spontaneous clearance of *Chlamydia trachomatis* infection in untreated patients. *Sexual Transmitted Disease* **24**(4): 229-235. Punnonen R, Terho P, Nikkanen V, Meurman O. (1979). Chlamydial serology in infertile women by immunofluorescence. *Fertility and Sterility Forum* **31**: 656 - 659.

Puolakkainen M, Hiltunen-Back E, Reunala T, Suhonen S, Lahteenmaki P, Lehtinen M, Paavonen J. (1998). Comparison of performances of two commercially available

tests, a PCR assay and a ligase chain reaction test, in detection of urogenital *Chlamydia trachomatis* infection. *Journal of Clinical Microbiology* **36**: 1489– 1493.

Ross JD and Stewart P. (2007). *Pelvic infection*. In: Edmonds K (editor). *Dewhurst's Textbook of Obstetrics and Gynaecology* 7th edition. Oxford UK: Blackwell Publishing Ltd, pp.414– 422.

Sturm-Ramirez K, Hunter B, Diop K, Ibruhim N. (2002). Molecular epidemiology of genital *Chlamydia trachomatis* infection in high risk women in Senegal. *West Africa Journal of Clinical Microbiology* **38**:138-145.

Weström L (1994). Sexually transmitted diseases and infertility. *Sexual. Transmitted Disease* **21**: 32–37.

Williams H, Tabrizi S, Lee W, Kovacs G, Garland S. (2003). Adolescence and other risk factors for *Chlamydia trachomatis* genitourinary infection in women in Melbourne, Australia. *Sexually Transmission Infection* **79**: 31–34.

Zegers-Hochschild F, Adamson J, de Mouzon O, Ishihare R, Mansoun K, Meygren E, Sullivan Vander poel S. (2009). ICMART and WHO Glossary on ART terminology. *Human Reproduction* **24**: 2683-2687.